Infectious Disease and Society: From Galen to Fauci

Over the past 4,000 years or so of “recorded” history, there have been numerous references to cataclysmic events affecting humankind. In addition to earthquakes, floods, and volcanic eruptions, there are descriptions of both recognizable and unknown diseases affecting humans and animals. From the beginning, these diseases—along with earthquakes and other natural disasters ---were associated with supernatural events. In both animist and theistic societies, the causes were ascribed to human behaviors that displeased one or more deities. Attempts to otherwise characterize diseases (and other significant occurrences affecting human life) by the early philosopher-scientists were often met with derision and, in some instances, persecution. Vestiges of this anti-science view persist today. This lecture/discussion series will provide a survey of infectious diseases over time, highlighting their impacts on the development and decline of entire societies. It is hoped this series will provide attendees with a better means to combat some of the falsehoods surrounding the characterization, prevention, and treatment of infectious diseases.

 

NoteThis course will not meet on Tuesday, November 11 and will resume the following the Tuesday.


Group Leader: Marc Mittelman
Venue: The Engineering Center
Meets on: Tuesday 10 AM
Starting: Oct 21
Sessions: 4
Class Size: 25
Teaching Style: Lecture with questions
Weekly Preparation: 1 - 2 hours

Dr. Marc Mittelman is a principal with Mittelman & Associates, a professional services firm specializing in microbiology consulting. He was previously an Associate Professor in the Faculties of Medicine and Dentistry, and director of the Centre for Infection and Biomaterials Research (CIBR) at the University of Toronto. Over the past 40 years, Marc has also held positions in the pharmaceutical and technical consulting industries. The majority of his research, teaching, and consulting work has been in detection and mitigation of microbiological contamination for pharmaceutical/biotechnology, clinical, and industrial applications. Marc has published over 85 peer-reviewed scientific works.